FDA Steps Up Alzheimer’s Initiatives, Plans October Stakeholders Meeting
This article was originally published in Pharmaceutical Approvals Monthly
Drug treatments and biomarker development for Alzheimer’s disease are on the agenda of a meeting FDA expects to hold in October with neurological organizations, Janet Woodcock, the agency’s chief medical officer, said during a July 25 audio conference sponsored by Avalere.
You may also be interested in...
Issues of clinical trial design are at the forefront in Alzheimer's drug development. Researchers and investors are weighing the impact of late-stage failures, even as significant unknowns remain about disease mechanism and the correlation of biochemical markers and clinical effects. A fundamental question hangs over AD drug development, which is unique in many respects: in deciding how to move from Phase II into Phase III, what can you know and how can you know it?
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.
Phase III data for Affymax/Takeda's anemia drug for chronic kidney failure signals potential regulatory hurdles in non-dialysis use.